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Available online 19 January 2014Schistosomiasis remains one of themajor neglected tropical diseases (NTDs) causingmorbidity
ofhumans residing in the tropical countries.Mucheffort hasbeendevoted to thedevelopment of
vaccines, since it is recognized that vaccines can be served as an important supplementary
component alongside chemotherapy for the future control and elimination of schistosomiasis.
To accelerate digging new potential target antigens, it is essential to extensively and intensively
search immunogenic proteins in a high-throughput manner using proteomics-microarray
techniques. In the present study, an integrated immunoproteomics and bioinformatics
approach was used to profile the tegument of the human blood fluke Schistosoma japonicum.
Results showed that the full-length tegument proteins were high-throughput cloned and
expressed and screenedwith sera from S. japonicum-infected patients and normal subjects using
protein arrays. Here, thirty highly immunoreactive tegument proteins and 10 antigens with an
AUC value greater than 0.90 were identified at first time. In particularly, STIP1, the highest
immunoreactive tegument protein has been shown good antigenicity and immunogenicity, and
thus makes it to be a potential target for designing anti-parasite drug or vaccine.
Biological significance
The schistosome tegument plays a crucial role in host–parasite interactions and there are
several tegument proteins that proved to be potential vaccine candidates. However,
vaccines are not yet available, thus it is important to identify new target antigens from
schistosome tegument proteome. Herein, we demonstrate that the S. japonicum tegument
proteins were analyzed by an integrated immunoproteomics and bioinformatics approach.
We found that thirty highly immunoreactive tegument proteins and 10 antigens with an
AUC value greater than 0.90 were identified for the first time. In particularly, we found 17
of tegument immunoproteomes having putative interaction networks with other proteins
of S. japonicum. The results will provide clues of potential target molecules for vaccine
development and biomarkers for diagnostics of schistosomiasis.
© 2014 The Authors. Published by Elsevier B.V. Open access under CC BY-NC-ND license.Keywords:
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Schistosomiasis remains one of the major neglected tropical
diseases (NTDs) causing morbidity of humans residing in
tropical countries, with an estimated 779 million people at risk
and 207 million infected people worldwide [1]. Schistosomiasis
is usually associated with some severe clinical symptoms and
the full impact of schistosomiasis in the world is no less than
that caused by other tropical diseases [2–4]. Nevertheless,
schistosomiasis is still a NTD, as the transmission of the
disease is only marginally affected by chemotherapy, and
rapid re-infection easily sustains its prevalence [5]. Indeed,
schistosomiasis japonica had re-emerged in several areas
where transmission control and elimination had been declared
in P. R. China [6]. In spite of the existence of highly effective
praziquantel (PZQ) for treatment, there are certain limitations
in the disease transmission control by chemotherapy alone, e.g.
mass treatment does not prevent re-infections, and the
potential risk of parasite resistance has been greatly concerned
when repeated mass chemotherapy was delivered in a long
term. Therefore, vaccination strategies represent an important
supplementary component alongside chemotherapy for sus-
tainable control of schistosomiasis [7].
Understanding the immune response to schistosome
infection, both in animal models and in humans, may
accelerate the development of a vaccine. For example, the
radiation-attenuated (RA) schistosome antigen remains
the most effective reagent inducing high levels of protective
immunity against schistosome in various animal models
(e.g. rodents, pigs and non-human primates) [8–10]. Recent-
ly, remarkable efforts were made in finding recombinant
antigens with protective efficacy. Immunization with the
recombinant proteins of Schistosoma mansoni, tetraspanin 2
(SmTSP-2), stomatin-like protein 2 (SmStoLP-2) and SmRho
in mice could induce protective immunity with significant
reduction of adult worm and liver egg burdens [11–14].
Similar pattern was also observed with S. japonicum recombi-
nant proteins including SjTP22.4, insulin receptor 2 and
UDP-glucose 4-epimerase protein [15–17]. However, all these
antigens reported previously could not produce highly
effective immunity for clinical use until now. Apparently, to
identify new target antigens should be pursued using the
information derived from schistosome genome and proteome
studies [18].
PZQ damages the adult schistosome tegument exposing
the surface antigens to the host immune system, inducing
specific host cellular and humoral immune responses to kill
the worms [19,20], resulted in some resistance to re-infection
and prevention from the development of severe disease forms
of S. mansoni and S. haematobium [19]. It is the most obvious
evidence that the schistosome tegument plays a crucial role
in the interaction of parasite and host immune system,
therefore, the tegumental proteins are recognized as prime
antigens in searching for vaccine candidates [21]. However,
the tegument proteins have not yet been extensively and
intensively searched. To this end, the proteomic studies are
able to identify hundreds of tegumental proteins, which
might speed up the development of vaccines against schisto-
somiasis [22].In this study, an integrated immunoproteomics and bioin-
formatics approachwas applied to profile tegument proteins of
S. japonicum, which provide a high-throughput manner for
screening hundreds of proteins at one time for immunogenic
antigens of interest leading to the clues of potential vaccine
target molecules and biomarkers for diagnostics.2. Materials and methods
2.1. Serum sample collection
Serum samples were obtained from patients in the annual
schistosomiasis surveillance in Anhui province, where
S. japonicum is endemic. The study was approved by the
Ethics Committee of the National Institute of Parasitic
Diseases (NIPD), China CDC. The study protocol, potential
risks, and benefits were explained to the villagers. After their
consent to perform the study, the field workers visited the
enrolled families, where detailed information was provided
to all participants, and questionnaires were applied. All
participants in a given household provided written informed
consent.
Collection of serum samples was conducted with the
approved protocol. All personal identifiers and medical infor-
mation were delinked from the serum samples and concealed.
Stool specimens were examined with the Kato–Katz thick
smear procedure as described [23]. Normal human serum
samples used as control in the studywere collected inShanghai,
a non-endemic region.
2.2. PCR amplification and In-Fusion cloning
The genes encoding full-length tegument proteins were
selected from the previous database of S. japonicum proteome
(http://function.chgc.sh.cn/sj-proteome/index.htm) [22]. A total
of 200 unique genes encoding tegument proteins of S. japonicum
were used for PCR amplification and In-Fusion cloning. Among
them, 54 proteins have specific protein domain analyzed by
SMART (Simple Modular Architecture Research Tool) software
(http://smart.embl-heidelberg.de/) [24], 19 proteins have signal
peptide (http://www.cbs.dtu.dk/services/SignalP/) and 16 pro-
teins have transmembrane domain [24,25].
Gene-specific primers were designed with Invitrogen Oligo-
Perfect Designer (http://tools.invitrogen.com/content.cfm?
pageid=9716) [26,27]. The nucleotide sequences with the signal
peptide were excluded from the gene expression constructs [25].
Each gene-specific sense and antisense primers were converted
into In-Fusion PCR primers for extending at the 5′-terminus with
the sequence 5′-GGG CGG ATA TCT CGA G-3′ and 5′-GCG GTA
CCC GGG ATC CTT A-3′, respectively. Plasmid DNA and ds cDNA
of S. japonicum were used for PCR amplifications of target genes
according to the previous reports [26,27].
The pEU-His vector (derived from pEU, CellFree Sciences,
Matsuyama, Japan) was used for In-Fusion cloning. The vector
was first linearized by double digestion with restriction
enzymes Xho I and BamH I (Takara, Japan) and cloned with
PCR products in a high-throughput manner as described
previously [26,27]. A target colony was selected for plasmid
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tion system (Viogene, Taipei, Taiwan), according to the
manufacturers' instructions. Highly purified DNA was eluted
in 50 μl 0.1 × TE buffer (10 mM Tris–HCl, pH 8.0, 1 mM EDTA)
and the concentration was tested by a NanoVue Plus
Spectrophotometer (GE Healthcare).
2.3. High-throughput expression of S. japonicum proteins and
western-blot analysis
S. japonicum proteins were expressed by a wheat-germ cell
free (WGCF) expression system, using the bilayer translation
reaction method which was described previously [28]. The
total fraction of 42 proteins was separated by sodium dodecyl
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) under
reducing conditions. The separated proteins were transferred
to 0.45 μm PVDF membranes (Millipore, Billerica, MA). After
blocking with 5% skim milk in TBS/T, Penta·His antibody
(QIAGEN) and secondary HRP-conjugated goat anti-mouse IgG
(Pierce) were used to detect His-tagged recombinant proteins.
The immunoblots were incubated with Diaminobenzidine
(DAB) and the results were documented by a ScanJet 5300C
Scanner (Hewlett-Packard).
2.4. Protein expression analyzed by protein array
OPEpoxy glass slides (75 × 25 mm) were used for protein arrays
(CapitalBio, Beijing, China). Teflon tapes with 200 holes (25 × 8,
diameter 1.5 mm) each were attached to the modified glass
slides to prepare well-type amine arrays [26]. 1 μl of each crude
S. japonicum protein solution was spotted to each well of
the arrays and incubated for 2 h at 37 °C. In addition, the
wells spotted with purified His-tagged S. japonicum saposin
(unpublished data) andwheat germ lysate without any plasmid
vector were set as the positive and negative controls, respec-
tively. The array was first blocked with 5% bovine serum
albumin (BSA) in PBS containing 0.1% Tween 20 (PBS-T) for 1 h
at 37 °C and incubatedwith Penta·His antibody (1 μl, 10 ng/μl) in
PBS-T for 1 h at 37 °C. The reactions were visualized with Alexa
Fluor 546 goat anti-mouse IgG (10 ng/μl, Invitrogen) in PBS-T for
1 h at 37 °C and scanned in a fluorescence scanner (LuxScan
10 K, CapitalBio, Beijing, China) [27]. Fluorescence intensities
of array spots were quantified by the fixed circle method
using ScanArray Express software version 4.0 (PerkinElmer).
The positive cut-off value was calculated as the mean fluores-
cence intensity value of the negative controls plus two standard
deviations (SD).Table 1 – Efficiency of PCR amplification and cloning of parasite
PCR (%)
In-Fusio
S. japonicum 97.0% (194/200) 99.0%
P. vivaxa 90.8% (99/109) 92.9
P. falciparumb 79.2% (152/192) 90.8%
Schistosomac 88.1% (244/277)
P. falciparumd 96.0% (922/960)
a, b, c, d The results of PCR amplification and cloning of parasite genes we
⁎ p < 0.05.2.5. Serum screening using protein arrays
Sera samples of pooled 10 S. japonicum patients and pooled
10 normal subjects were used for primary screening on
well-type amine arrays. Briefly, 1 μl of each protein solution
was spotted in duplicate to each well of the microarrays and
incubated for 2 h at 37 °C. The chips were then probed with
the pooled serum samples (1:200) which were pre-absorbed
against wheat germ lysate (1:10) to block the anti-wheat
germ antibodies. The bound antibodies were visualized with
Alexa Fluor 546 goat anti-human IgG (10 ng/μl, Invitrogen)
in PBS-T and quantified as described above. The higher
response of a probed protein against the patient serum
sample was considered to be positive, when the relative
ratio of signal intensity (SI) was >2.0 compared with the
response to the normal sera. The Benjamini–Hochberg
method was used to correct the false discovery rate using
MULTTEST procedure in version 8.0 of SAS/STAT software
[29].
After primary screening, 30 proteins with high immunore-
activity were screened again with 10 individual positive
serum samples and 10 individual normal serum samples
which were used to constitute pooled samples in the primary
screening. The second screening was run on one array for
further confirmation.
2.6. Cloning, production, and purification of recombinant
STIP1 and PPase
The genes encoding top 2 immunogenic proteins (STIP1,
SJCHGC06661 and PPase, SJCHGC07024) were cloned into
pET-28a vector using In-Fusion PCR primers between two
restriction sites: BamH I and Xho I. The vectors were then
transformed into Escherichia coli strain BL21 (DE3) for expression
of the recombinant STIP1 and PPase proteins. Bacteria were
cultures in LB broth at 37 °C to anA600 nmof 1.4. Expressionwas
induced with 0.7 mm isopropyl 1-thio-β-D-galactopyranoside
(IPTG), and bacteria were grown for a further 9 h at 37 °C. The
suspension was harvested by centrifugation at 5,000 rpm (4 °C)
for 8 min and the pellet was resuspended in Ni column buffer A
(300 mMNaCl, 50 mM phosphate buffer pH 7.4, 10 mM imidaz-
ole, 10% glycerol) containing 5 mM PMSF and lysed by sonica-
tion. The lysate was clarified by centrifugation 13,000 rpm
(4 °C) for 30 min, and the supernatant was filtered by 0.22 μm
filter membrane and purified by an affinity chromatography
column of nickel-nitrilotriacetic acid (Ni-NTA) resin, using an
ÄKTA purifier 10 (GE Healthcare). The eluted protein wasgenes.
Cloning methods
n cloning (%) Homologous recombination (%)
(192/194) –
% (92/99) ⁎ –
(138/152) ⁎ –
– 100.0% (244/244)
– 97.0% (715/737)
re published in the previous reports [26,27,33,34].
Fig. 1 –Western blot analysis of the expression level of Schistosoma japonicum proteins. Forty-two of S. japonicum proteins were
detected by anti-His6-tag antibody.
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NaCl, 10% glycerol. The purified proteins were separated by
SDS-PAGE under reducing conditions and transferred to 0.45 μmFig. 2 – Antibody profiling of Schistosoma japonicum tegument pr
anti-His6-tag antibody and detected by Alexa Fluor 546 goat anti-
lacked vector template (circle) and reactions of purified His-tagge
S. japonicum tegument proteins react with pooled serum from na
serum from normal subjects (right panel). Wheat germ lysate tha
(circles) probed with patient and normal serum served as inner n
S. japonicum tegument proteins with high immunoreactivity wer
exposed S. japonicum patients (top panel) and 10 normal subjectPVDF membranes (Millipore, Billerica, MA). After blocking with
5% skim milk in TBS/T, Penta·His antibody (QIAGEN) and
secondary HRP-conjugated goat anti-mouse IgG (Pierce) wereoteins by protein arrays. A), Protein arrays probed with
mouse IgG. Control reactions of wheat germ lysate (WGE) that
d S. japonicum saposin (rectangular box). B), Crude
turally exposed S. japonicum patients (left panel) and pooled
t lacked vector template (hexagons) and purified saposin
egative and positive controls, respectively. C), Crude
e screened again with sera from these 10 cases of naturally
s (bottom panel) together on one array.
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blots were incubated with DAB.
The recombinant STIP1 and PPase proteins were detected
in the pooled serum from 10 cases of S. japonicum-exposed
individuals and unexposed subjects (1:200), respectively.
Bound antibodies were detected by incubation in secondary
HRP-conjugated goat anti-human IgG (Sigma) and the immu-
noblots were incubated with DAB. The results were docu-
mented by a ScanJet 5300C Scanner.
2.7. Inducing polyclonal antibodies against recombinant STIP1
and PPase
Eight to ten week-old C57 mice were subcutaneously inocu-
lated with 20 μg of recombinant STIP1 and PPase emulsified in
Freund's complete adjuvant (FCA) on day 0. Two boosters
were given on days 14 and 28, using the same proteins
emulsified in Freund's incomplete adjuvant (FIA), PBS was set
as the negative control. Animal care was performed in
accordance with institutional guidelines. Animal sera were
collected at days 28. A previously described ELISA test was
used for determining inoculated protein immunogenicity.
Briefly, each of the inoculated proteins was coated in 96-well
ELISA plates and incubated at 1:200 dilution of each serum
and a HRP-conjugated goat anti-mouse IgG (Pierce) was used
as the secondary antibody.
2.8. Data analysis
Differences in proportions were compared using a χ2 test. The
area under the receiver operating characteristic (ROC) curve
(AUC) and a two-tailed unpaired Student t-tests were used to
evaluate the immunoreactivity of the recognized antigens by
GraphPad Prism software, version 5.0 (GraphPad, San Diego,
CA). Statistical differences of p < 0.05 were considered
significant. The heatmap of antibody responses was drawn
using the TIGR multi-array experiment viewer (MeV) software
[30]. Data of conserved cysteine residues was analyzed by
WebLogo (http://weblogo.berkeley.edu/logo.cgi) [31]. Interac-
tion networks of tegument proteins were analyzed by STRING
tools (http://string-db.org/) [32].Fig. 3 – Tegument immunogenic proteins of Schistosoma
japonicum. The immunoreactivities of the proteins probed
with serum samples from S. japonicum patients (Sj1–Sj10)
and normal subjects (N1–N10) are depicted as a heatmap
with antigen IDs listed on the right.3. Results
3.1. PCR amplification of genes and In-Fusion cloning
The design flow of In-Fusion cloning primers for the PCR
amplification has shown in [26]. Out of 200 S. japonicum genes
selected for PCR amplification, 194 genes were amplified
successfully (Table 1). Four colonies per transformation were
selected at random for screening by colony PCR to evaluate
the efficiency of In-Fusion cloning. The screening results
showed that of the 194 genes screened, 192 were successfully
cloned (99.0%), which is significantly high than the efficiency
of the cloning of Plasmodium genes (p < 0.05; Table 1).
However, the results were consistent with the reports by
other studies for high-throughput construction of expression
vectors of Plasmodium falciparum and Schistosoma using the
homologous recombination in E. coli [33,34].3.2. High-throughput expression of S. japonicum proteins
To confirm the expression level of the S. japonicum proteins
expressed by WGCF, approximately one fifth (i.e. 42/192) of
the recombinant N-terminal His6-tag fusion proteins were
detected by western blot with Penta·His antibody specific to
the His6-tag epitope of the His6-tagged fusion proteins. Forty
of the 42 open reading frames (ORFs) (95.2%) yielded protein
products (Fig. 1). Though the genes from S. japonicum have
higher A/T contents (64% in average) than that of P.vivax (58%
in average), the tegument proteins of S. japonicum are easily
expressed by WGCF system [35]. Moreover, this result was
similar to data reported by our previous studies for
high-throughput expression of Plasmodium proteins by WGCF
[26,27].
3.3. Antibody profiling by protein arrays
We evaluated the efficiency of S. japonicum protein expression
with the Penta·His antibody by comparing protein arrays
(Fig. 2A). About 98.4% (189/192) of the S. japonicum proteins
were positive for the His6-tags on the array indicating
successful expression. Two arrays coated with the target
proteins were probed with the pooled positive and pooled
normal serum samples, respectively (Fig. 2B, left panel and
right panel). The positive serum showed significantly higher
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serum with low reactivity. After primary screening, 30
proteins with high immunoreactivity were re-screened, but
using the individual serum samples from S. japonicum patients
and normal subjects on the same array (Fig. 2C). The patterns
of antibody response to the antigens were obviously different
between the wells probed with positive and normal serum
samples.
3.4. The immunogenic proteins of S. japonicum tegument
The profiles of 30 highly immunoreactive tegument proteins
(15.0% of total target proteins) are shown in Fig. 3, and the SI
(signal intensity) of the reactivity of each antigen by individual
serum samples is shown in a colorized matrix. All of the 30
tegument proteins identified are previously uncharacterized
S. japonicum antigens. Fifteen of these proteins were recognized
by more than 5 individual patient sera. Moreover, one protein
(SJCHGC07024) was recognized by 9 individual patient sera
(90%). Phosphoglycerate kinase (SJCHGC09293) was recognized
by 7 individual patient sera (70%), which was a common
antigenic protein in human parasitic worms. This protein
has already been found in the patients of S. mansoni and
Clonorchis sinensis [36,37]. A 78 kDa glucose-regulated protein
(GRP78, SJCHGC06292) was recognized by 4 individual patientTable 2 – Features of S. japonicum tegument immunogenic prot
Protein ID AUC p value Recognitiona
MW (kDa)
SJCHGC06661 0.95 1.36E−04 80% 36.2
SJCHGC07024 0.93 2.63E−04 90% 32.7
SJCHGC02147 0.93 5.50E−03 40% 53.6
SJCHGC00692 0.93 2.10E−03 30% 41.7
SJCHGC05998 0.91 3.72E−04 70% 13.6
SJCHGC06209 0.91 1.63E−03 70% 20.9
SJCHGC09293 0.90 1.40E−03 70% 44.3
SJCHGC04616 0.90 6.94E−04 70% 21.0
SJCHGC04941 0.90 6.38E−04 70% 22.3
SJCHGC02336 0.90 1.23E−03 60% 38.7
SJCHGC04088 0.89 9.41E−04 60% 13.4
SJCHGC00665 0.89 2.79E−03 50% 38.9
SJCHGC05973 0.88 1.47E−03 60% 19.2
SJCHGC06292 0.88 1.50E−02 40% 71.5
SJCHGC02838 0.87 2.23E−03 60% 58.6
SJCHGC06812 0.87 2.55E−03 60% 16.2
SJCHGC06103 0.86 2.16E−03 60% 33.9
SJCHGC01035 0.86 2.58E−02 30% 23.2
SJCHGC05710 0.86 2.64E−03 50% 37.0
SJCHGC06939 0.86 1.82E−03 50% 20.6
SJCHGC01771 0.85 5.40E−03 40% 28.3
SJCHGC00865 0.85 1.12E−02 30% 46.1
SJCHGC06549 0.83 2.66E−03 50% 14.5
SJCHGC01793 0.83 1.35E−02 40% 44.2
SJCHGC00277 0.82 1.91E−02 50% 16.0
SJCHGC01311 0.81 1.42E−02 30% 55.7
SJCHGC06314 0.81 2.54E−02 30% 22.4
SJCHGC05608 0.79 3.01E−02 30% 32.9
SJCHGC06009 0.77 3.47E−02 30% 26.7
SJCHGC06246 0.72 7.11E−02 30% 28.7
a Total number of positive antibody reaction with individual 10 patient s
b SP, signal peptide was analyzed by SignalP 4.0 Server (http://www.cbs.d
c TMD, transmembrane domain and protein domain were analyzed by Ssera (40%), which has identified to be a homologue protein of
Leishmania donovani with strong immunogenicity [38].
The AUC value 1.0 denotes a perfect differentiation of
reactivity generated by patient sera and normal control,
respectively. An AUC of 0.5 for an antigen suggests that the
distribution of intensity values of patient sera and normal
control cannot be distinguished. Above 0.5, the higher the
AUC value of an antigen, the better differentiation is likely
made between the reactivities presented by patient sera
and normal control [33]. When ranked by AUC values, all of
the 30 antigens have an AUC value greater than 0.70, among
them 10 antigens (33.3%) > 0.90 (1.36e−4 < p > 5.5e−3), 17
antigens (56.7%) > 0.80 (9.41e−4 < p > 2.58e−2) and 3 antigens
(10%) > 0.7 (3.01e−2 < p > 7.11e−2) (Table 2). One protein (STIP1,
SJCHGC06661) with TPR/STI1 domain has a highest AUC value
(0.95, p = 1.36e−4) and could be recognized by 8 patients' sera.
From a total of 192 screened S. japonicum proteins in the
array for antibody response, 8 tegument proteins contain
specific protein domain namely TPR domain/STI1 domain,
ACTIN domain, A1pp domain, PDZ domain, RRM domain, S1
domain, PHB domain and SapB domain, respectively (Table 2).
When gene family and domain variations were compared
between schistosomes and metazoans, it has shown that
~1,000 protein domains have been abandoned by S. japonicum,
including some involved in basic metabolic pathways andeins.
pI SPb TMDc Protein domainc
6.09 No 0 TPR/STI1 domain
5.93 No 0 No
5.76 Yes 0 No
5.30 No 0 ACTIN domain
4.68 Yes 0 No
7.70 No 0 A1pp domain
7.06 No 0 No
9.30 No 0 PDZ domain
5.40 No 0 No
7.31 No 0 No
9.73 No 0 No
5.88 No 0 No
7.86 No 0 No
5.03 Yes 0 No
8.87 Yes 0 No
5.46 No 0 No
7.17 No 0 No
11.58 No 0 RRM domain
4.68 No 0 S1 domain
8.84 No 0 No
7.35 No 0 No
5.77 No 0 PHB domain
4.37 No 0 No
9.24 No 0 No
5.92 No 1 SapB domain
6.51 Yes 0 No
8.28 No 0 No
8.19 No 0 No
5.50 No 0 No
11.35 No 0 No
erum samples.
tu.dk/services/SignalP/).
MART (http://smart.embl-heidelberg.de/).
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partly, a consequence of the adoption of a parasitic way of life
[35].
Proteins containing SapB domain are popularly seen in
the schistosome genome and proteome. By searching through
the complete S. japonicum genome sequence data, 14 genes
identified in this study were found to be conformable to the
characteristics of a gene family containing 21 SapB domains
(Fig. 4A), the saposin-like protein (SAPLIP) family, which
composed of distantly related polypeptides that have six
conserved cysteine residues forming three disulfide bridges
(Fig. 4B). SAPLIPs have been reported from the gastrodermis of
related flukes, and at least one is hemolytic and a promising
vaccine antigen [39].
3.5. Interaction networks of S. japonicum tegument
immunogenic proteins
Interaction networks of S. japonicum tegument immunogenic
proteins were analyzed and 17 highly immunoreactive
proteins (56.7%, 17/30) were found to be interactive with at
least one protein of S. japonicum, in which 12 proteins have
interactions with more than 10 other proteins. Interaction
networks of the highest immunogenic tegument protein
(STIP1, SJCHGC06661) with other proteins of S. japonicum
were shown in Fig. 5A. The interaction behavior of other 3
tegument proteins including heat shock protein HSP 90-alphaFig. 4 – Saposin-like proteins of Schistosoma japonicum. A), The a
proteins are marked with pink underline and rectangular box. B
features. The invariable cysteine residues are displayed in green
properties: polar amino acids are green, basic are blue, acidic are2 (HSP90, SJCHGC00820), DnaJ homolog subfamily Amember 1
(HSP40, SJCHGC01085) and heat shock 70 kDa protein 9
precursor (HSP70, SJCHGC06312) was noted though these
tegument proteins have low immunoreactivity (Fig. 5B).
Generations of compounds with high affinity and specificity
for different cochaperone proteins can be used as chemical
probes to dissect the complex Hsp90–cochaperone interac-
tions, with the potential to be developed into novel antipar-
asitic drugs [40].
3.6. Antigenicity and immunogenicity of the recombinant
STIP1 and PPase
SDS-PAGE analysis showed that the bands of purified recom-
binant STIP1 and PPase proteins appeared at about 36 kDa and
32 kDa, respectively, which were similar to the predicted size
(Fig. 6A&B). Furthermore, western blot analysis showed the
specific bands of STIP1 and PPase detected by anti-His
antibody (Fig. 6A&B). The recombinant STIP1 and PPase
proteins were also detected in the pooled serum from 10
cases of S. japonicum-exposed individuals rather than unex-
posed subjects (Fig. 6A&B), which indicated the naturally
acquired humoral immune responses of recombinant STIP1
and PPase against S. japonicum infections.
Antibody titers of the recombinant STIP1 and PPase
proteins were determined in immunized C57 mice. Stronger
antibody titers were generally observed in the recombinantlignment of Saposin-like proteins of S. japonicum. Tegument
), The corresponding sequence logo reveals the conserved
. Amino acids are colored according to their chemical
red and hydrophobic amino acids are black.
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0.51 and 0.51) than PBS immunized mice (mean OD450 nm, 0.05
and 0.02) with significant difference (p < 0.001) (Fig. 6C). The
formulations have been shown good immunogenicity of the
recombinant STIP1 and PPase proteins.Fig. 5 – Analysis of the interaction networks between highest im
proteins of Schistosoma japonicum. A), Map of interaction networ
B), Detail description of S. japonicum proteins involving the intera
shock protein HSP 90-alpha 2 (HSP90, SJCHGC00820), DnaJ homo
shock 70 kDa protein 9 precursor (HSP70, SJCHGC06312) interact
domains and one STI1 domain.4. Discussion
Most commercially available vaccines rely specifically on the
induction of neutralizing antibodies that block the function ofmunogenic tegument protein (SJCHGC06661) and other
ks between SJCHGC06661 and other proteins of S. japonicum.
ction network. Three tegument proteins we expressed, heat
log subfamily A member 1 (HSP40, SJCHGC01085), and heat
with tegument protein (SJCHGC06661) which has six TPR
Fig. 6 – Antigenicity and immunogenicity of the recombinant STIP1 and PPase proteins of Schistosoma japonicum. A), SDS-PAGE
analysis of the expression of recombinant STIP1 (left panel) and western blot analysis of the recombinant STIP1 against
anti-His antibody, S. japonicum-exposed individuals and unexposed subjects, respectively (right panel). B), SDS-PAGE analysis
of the expression of recombinant PPase (left panel) and western blot analysis of the recombinant PPase against anti-His
antibody, S. japonicum-exposed individuals and unexposed subjects, respectively (right panel). C), Stronger antibody titers
were generally observed in the recombinant STIP1 and PPase protein immunized mice than PBS immunized mice (p < 0.0001).
297J O U R N A L O F P R O T E O M I C S 9 8 ( 2 0 1 4 ) 2 8 9 – 2 9 9their target proteins, and this appears to also be the case for
helminth vaccines, where neutralizing antibodies block pro-
teins that have biological roles [5]. PZQ treatment damages
the adult schistosome tegument and then resulting in some
resistance to re-infection of S. mansoni and S. haematobium,
thus it is important to identify new target antigens from
schistosome tegument proteome [19].
The ability of protein array technique to detect specific
antibody responses to a number of antigens in parallel in a
high-throughput way has significant implications for vaccine
target discovery [34,41]. Recently, protein arrays were used
to characterize antibody reactivity profiles of P. vivax and
P. falciparum infection [26,27]. Protein arrays were also used to
characterize antibody reactivity profiles with the serum from
Schistosoma infected rabbits [34,42]. In the present study, the
same platform of protein arrays was used to characterize
antibody reactivity profiles of S. japonicum infection in human.
From 192 tegument proteins screened by protein arrays, 30
(15.6%, 30/192) highly immunoreactive proteins were identi-
fied. All the highly immunoreactive tegument proteins were
not characterized from previous literatures.
Many surface proteins share similar characteristics con-
taining cysteine-rich domains that are of potential signifi-
cance in adherence and vaccine targets. They include 6-cys
family of Plasmodium and the surface antigen (SAG) relatedsequence (SRS) super-family of Toxoplasma [43,44]. Recently,
lytic proteins were identified from two liver fluke species:
clonorin from C. sinensis and FhSAP1 and FhSAP2 from
Fasciola hepatica [45,46]. Recombinant FhSAP2 showed protec-
tive efficacy against challenge infection with F. hepatica and
provided cross-protection in mice experimentally infected
with S. mansoni [47]. The results indicate that SAPLIPs have
the potential as attractive broad-spectrum protective targets
for parasite vaccines. One S. mansoni SAPLIP (Sm-SLP-1) is
expressed in the gastrodermis of the worm, which is
immunogenic in humans and mice, but not protective in its
current form. However, there was no experimental evidence
of immunogenicity and protective effect for other SAPLIPs of
S. mansoni. Most recently, the first three-dimensional crystal
structures of SAPLIPs from hookworms and ecdysozoan
organisms, namely Na-SLP-1 and Ac-SLP-1 were reported
and both SAPLIPs share the property of membrane binding
activity [48].
In our tegument immunoproteome study, one highly
immunoreactive tegument protein (SJCHGC00277) containing
a SapB domain belongs to SAPLIP family. It is a diverse family
of lipid-interacting proteins, of which their cellular functions
were only partially understood [49]. A search of the complete
S. japonicum genome sequence identified 14 protein members
conforming to the characteristics of this family and most of
298 J O U R N A L O F P R O T E O M I C S 9 8 ( 2 0 1 4 ) 2 8 9 – 2 9 9S. japonicum SAPLIPs only had one SapB domain (data not
shown). Another tegument protein (SJCHGC01869), which has
five SapB domains, has showed low immunoreactivity. It may
be attributed to the low expression level due to the high
molecular weight of the protein (922 aa and 104.2 kDa). The
gene family coding saposin-like proteins (SAPLIPs) may play
important roles in host–pathogen interactions and have high
potential as vaccine targets against schistosome infection.
The tetratricopeptide repeat (TPR) domain is a degenerate
34 amino acid sequence that occurs in tandem repeats in
the protein. Proteins containing TPRs are involved in a variety
of biological processes, such as cell cycle regulation, tran-
scriptional control, mitochondrial and peroxisomal protein
transport, neurogenesis, protein folding and protein binding
[50,51]. A TPR-domain protein P. falciparum (PfPP5) is destined
to have a definitive role in parasite growth and signaling
pathways. This is exemplified by the interaction between
PfPP5 and the cognate chaperone HSP90 [52]. The highest
immunogenic tegument protein (STIP1, SJCHGC06661) with
six TPR domains and one STI1 domain had an AUC of 0.95 and
was recognized by 8 cases (80%) of S. japonicum patient sera.
Analysis of the biological process of STIP1 showed that it may
involve in physiological process and response to stress.
Schistosome heat shock proteins (HSPs) were found to exert
dual immunoregulatory effects, including immunostimulatory
and immunosuppressive roles [53,54]. SJCHGC06661 is a
putative stress inducible protein 1 (STIP1) and might have an
important role in interaction with HSP complex. In fact, STIP1
was predicted to have a direct functional interaction with three
other tegument proteins (HSP90, HSP70 and HSP40) that we
expressed, and to have a STIP1 binding site. The recombinant
STIP1 (SJCHGC06661) was recognized by S. japonicum-exposed
individuals and has been shown good immunogenicity in
immunized mice, indicating that STIP1 could be one of the key
factors for the response to stress, and a potential target for
designing anti-parasite drug or vaccine.5. Conclusion
In present study, the S. japonicum tegument proteins were
analyzed by an integrated immunoproteomics and bioinfor-
matics approach. Thirty highly immunoreactive proteins were
identified for the first time,whichwill provide clues of potential
target molecules for vaccine development, biomarkers for
diagnostics, and the function identification of unknown and
hypothetical proteins in the S. japonicum genome.Acknowledgments
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